Cefazolin with vancomycin
PreclinicalSmall molecule
Cefazolin with vancomycin is one of 8 small molecule programs targeting Double-blind. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Double-Blind
#DrugCompanyPhaseTrials
1Olumiant
Eli LillyPhase 3
Albenza
IImpax Laboratories, LLC
Phase 3
Everolimus and Lonafarnib
BBoston Children's Hospital
Phase 3
Inosine Pranobex
NNewport Pharmaceuticals International
Preclinical
PORT-77
PPortal Therapeutics, Inc.
Phase 1
Western Therapy
JJiangxi Qingfeng Pharmaceutical Co. Ltd.
Preclinical
Interferon Alfa-N3
IInterferon Sciences
Preclinical
Cefazolin with vancomycin
CChang Gung Memorial Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Double-blind1 trial
Preoperative Daptomycin Prophylaxis in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial
Not yet recruiting·—·N/A·NCT06189885·184 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cefazolin with vancomycin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- CChang Gung Memorial Hospital